Symbicort 80/4.5
Pro Research Analysisby 
Searched over 200M research papers for "symbicort 80/4.5"
Clinical Efficacy and Safety of Symbicort 80/4.5 in Asthma Management
Introduction to Symbicort 80/4.5
Symbicort 80/4.5, a combination of budesonide (an inhaled corticosteroid) and formoterol (a long-acting beta2-adrenergic agonist), is widely used for the management of asthma. This article synthesizes recent research findings on the efficacy and safety of Symbicort 80/4.5 in treating asthma.
Efficacy in Improving Lung Function and Asthma Control
Comparative Studies with Pulmicort
Several studies have demonstrated that Symbicort 80/4.5 is more effective than Pulmicort (budesonide alone) in improving lung function and asthma control. In a randomized clinical trial, patients receiving Symbicort 80/4.5 showed significant improvements in spirometry parameters such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF) compared to those receiving Pulmicort1. Additionally, the Asthma Control Test (ACT) scores were significantly better in the Symbicort group, indicating superior asthma control1.
Dose-Response Relationship
Research comparing different dosages of Symbicort has shown that higher doses (160/4.5) provide more significant improvements in respiratory parameters and asthma control than the lower dose (80/4.5)1 2. However, even at the lower dose, Symbicort 80/4.5 effectively improves lung function and reduces asthma symptoms2.
Safety and Tolerability
Adverse Events and Safety Profile
Symbicort 80/4.5 has been found to be well-tolerated in both children and adults. In a study involving children aged 4 to 17 years, Symbicort 80/4.5 was as well-tolerated as budesonide alone, with most adverse events being mild to moderate in severity4. Similarly, in adults, Symbicort demonstrated a safety profile comparable to its monocomponents, with no unexpected patterns of abnormalities5.
Long-Term Safety
Long-term studies have confirmed the safety of Symbicort 80/4.5. Over a 52-week period, patients using Symbicort showed no significant differences in adverse events compared to those using budesonide alone, even at higher doses5. This indicates that Symbicort is a safe option for long-term asthma management.
Cost-Effectiveness and Treatment Strategies
Maintenance and Reliever Therapy (SMART)
The SMART regimen, which uses Symbicort for both maintenance and as-needed relief, has been shown to reduce asthma exacerbations and treatment costs compared to fixed dosing regimens. Studies have found that the SMART approach leads to fewer exacerbations and lower medication costs while maintaining similar levels of asthma control3 6. This makes Symbicort 80/4.5 a cost-effective option for asthma management.
Adjustable Dosing
Adjustable dosing of Symbicort, where patients can modify their dose based on symptom control, has also been effective. This strategy allows for reduced medication use and costs while maintaining or improving asthma control7 10. Patients on adjustable dosing regimens experienced fewer exacerbations and required fewer daily inhalations compared to those on fixed dosing regimens10.
Conclusion
Symbicort 80/4.5 is an effective and safe option for the management of asthma. It improves lung function and asthma control more effectively than budesonide alone and is well-tolerated in both children and adults. The SMART regimen and adjustable dosing strategies further enhance its cost-effectiveness and clinical benefits. These findings support the use of Symbicort 80/4.5 as a valuable treatment option for patients with persistent asthma.
Sources and full results
Most relevant research papers on this topic
Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control
Symbicort 160/4.5 mg/inhalation has higher efficacy in reducing asthma symptoms and improving asthma control compared to low doses and Pulmicort.
RCT
Rigorous JournalEffect of Different Specifications of Symbicort Turbuhaler on the Treatment of Patients with Bronchial Asthma
Different sizes of symbicort turbuhaler effectively control bronchial asthma, promote rapid recovery, and improve respiratory status with ideal safety.
RCTMaintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma:an efficacy and cost-effectiveness study
SMART treatment with budesonide/formoterol maintenance and formoterol as needed is 30-40% less expensive than 2 2 FIX + F treatment, maintaining equal asthma control and reducing medication costs.
RCT
Large Human Trial
Highly CitedPosters Group 2 ‐ Late abstracts
Symbicort is more effective and as well tolerated as budesonide alone for children with persistent asthma not fully controlled on inhaled corticosteroid alone.
RCTTreatment of Persistent Asthma With Symbicort® (Budesonide/Formoterol Inhalation Aerosol): An Inhaled Corticosteroid and Long-Acting β2-Adrenergic Agonist in One Pressurized Metered-Dose Inhaler
Symbicort is an effective and well-tolerated inhaled corticosteroid and long-acting beta2-adrenergic agonist combination for treating persistent asthma in patients aged 12 and older.
Systematic ReviewBudesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma.
The SMART regimen using budesonide/formoterol for both maintenance and as-needed symptom relief significantly reduces asthma exacerbations compared to fixed-dose combination and higher fixed-dose ICS alone in children.
RCTLarge Human TrialHighly CitedAdjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study.
Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma control at reduced medication doses, with no treatment failures.
RCTLarge Human TrialBudesonide/formoterol improves lung function compared with budesonide alone in children with asthma 1
Budesonide/formoterol significantly improves lung function in children with asthma compared to budesonide alone, making it a safe and effective treatment option.
RCTLarge Human TrialZ7200 versus Symbicort® Turbohaler®: A pharmacodynamic evaluation of the acute effects using functional respiratory imaging (FRI)
Z7200 and Symbicort® show no difference in efficacy parameters, despite half the delivered dose of Z7200.
BUDESONIDE/FORMOTEROL ADJUSTABLE MAINTENANCE DOSING REDUCES ASTHMA EXACERBATIONS VERSUS FIXED DOSING
Adjustable maintenance dosing with budesonide/formoterol provides more effective asthma control and reduces costs compared to fixed dosing.
RCTLarge Human TrialRigorous Journal